智通财经APP获悉，澳大利亚的人工心脏瓣膜制造商Anteris Technologies 周一宣布了其 IPO 条款。该公司计划以每股6.78美元的价格发行1,480万股股票，以筹集1亿美元资金。按照拟议价格，Anteris Technologies的市值将达到2.44亿美元。
该公司的股票目前在澳大利亚证券交易所上市，代码为“AVR”。6.78美元的定价是其股票在澳大利亚证券交易所12 月 5 日的收盘价。
Anteris是一家专注于主动脉狭窄患者的结构性心脏公司。其主导产品DurAVR经导管心脏瓣膜(THV)系统由单件式仿生瓣膜组成，迄今为止，美国、加拿大和欧洲共有73名患者接受了DurAVR THV系统的治疗。
该公司成立于1999年，截至2024年9月30日的12个月收入为300万美元。该公司计划在纳斯达克上市，股票代码为AVR。Anteris于2024年2月14日秘密提交了申请。TD Cowen、巴克莱和Cantor Fitzgerald是此次交易的联合簿记行。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.